Canadian patients who receive brand-name adalimumab (Humira) to treat ankylosing spondylitis (AS) are eligible for a patient support program, provided by drug maker AbbVie, that includes personalized services such as coaching phone calls before and after initiating treatment.
Canadian patients who receive brand-name adalimumab (Humira) to treat ankylosing spondylitis (AS) are eligible for a patient support program, provided by drug maker AbbVie, that includes personalized services such as coaching phone calls before and after initiating treatment.
A newly published study, funded by AbbVie and published in Rheumatology and Therapy, used de-identified patient-level records from the Quintiles IMS longitudinal prescription transactions database to assess the likelihood of patients who were enrolled in the patient program to achieve controlled AS, as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), compared with patients who were not enrolled in the program.
The researchers identified 249 patients with AS who received their first adalimumab prescription between January 2010 and October 2015, and who were persistent on their adalimumab therapy. Of this group, 123 patients received coaching calls as part of the patient program. All of the patients had a BASDAI assessment between 90 days before and 30 days after the date of the first prescription, and a follow-up assessment 6 to 18 months later.
The researchers found that, at the follow-up BASDAI assessment, 80% (n = 98) of patients who received coaching as part of the assistance program had reached controlled disease, versus 68% of patients (n = 86) who did not receive any coaching. After adjusting for age, sex, region, biologic-naïve status, disease status at baseline, and time between assessments, coaching was associated with an increased probability of controlled AS (risk ratio, 1.23; 95% CI, 1.06-1.42; P  = .0055).
While previous research has demonstrated that patient programs are associated with improved adherence to adalimumab therapy, “To our knowledge, the [coaching] is the first example of a patient-centric service that was associated with improved clinical outcomes,” write the authors. These data, they say, should both encourage physicians to enroll patients in assistance programs, and encourage drug developers to invest in and refine these programs to help patients beyond providing medications.
The researchers acknowledge that this study had a relatively small sample size, and that limited data on baseline disease characteristics or lifestyle factors were available for the patients. However, they suggest that future investigation of these additional factors may be conducted through self-reporting by patients, including in-depth patient interviews.
Reference
Bessette L, Lebovic G, Millson B, et al. Impact of the adalimumab patient support program on clinical outcomes in ankylosing spondylitis: results from the COMPANION study. [Published online April 9, 2018] Rheumatol Ther. doi: 10.1007/s4074.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.